We continue to take a look at some of the movers here on Wall Street. Diane King Hall is with me and looking at more of the uh chip and tech kind of names and including Micron. Um and this is a key one.Let's take a look. >> I know uh Wedbush seeing even more reason to room room to run from here for Micron. Now they are already already bullish.They're overweight on this stock, but they're lifting their price target to 300. So they see more upside from here. And I mean this is with a stock that's sitting at j ...

Core Insights - Abbott Laboratories' Nutrition business is experiencing strong growth and market share gains, driven by high demand for adult nutritional products that combine high protein and low sugar [1][7] - The global nutritional supplements market is projected to reach $704.28 billion by 2030, growing at a CAGR of 6.42% from 2025 to 2030, influenced by increased health consciousness post-COVID-19 and rising non-communicable diseases [2] - Abbott's brands, Ensure and Glucerna, are leading in the market for complete nutrition, while the Similac brand remains the top choice for pediatric nutrition in the U.S. [3][7] Company Performance - Abbott's adult Nutrition segment achieved 6.6% organic growth in Q2 2025, contributing to mid-single-digit organic growth overall [3][7] - Year-to-date, Abbott shares have increased by 16.5%, outperforming the industry growth of 5.9% and the S&P 500's 9.6% [6] Competitive Landscape - Nestlé's Nutrition business offers a wide range of products for all life stages, including infant formulas and adult nutritional drinks [4] - Danone specializes in Early Life Nutrition and Medical Nutrition, providing a variety of infant and child nutrition products as well as condition-specific solutions [5] Valuation Metrics - Abbott currently trades at a forward Price-to-Sales (P/S) ratio of 4.89X, below the industry average of 5.56X [8]